Both tirzepatide (Mounjaro) and semaglutide (Ozempic) have made headlines in recent months for their benefits in broad patient populations. This new analysis compared the two medications in obese/overweight adults with and without type 2 diabetes.

The average payment rate to physicians is suggested to be reduced by 2.93% in 2025 under the proposed fee schedule change, the agency noted. 

Researchers explored more than 100,000 online reviews, using AI to learn as much as possible about what drives patients to give their cardiologist a positive or negative rating.

Care teams gained significant momentum in the early days of TAVR. Now, however, they are being used to address a wide variety of cardiovascular concerns. 

According to the new proposal, the 2025 conversion factor would be $32.36, down approximately 2.8% from 2024. SCAI, MGMA and other groups have already stepped forward with warnings that these cuts could do significant damage to patient care. 

The American Medical Association says payment policies are challenging the viability of smaller physician practices, which will eventually cause healthcare access issues.

Value-based payments can impact cardiology practices in many ways, helping cardiologists acquire new technology and boost patient care.

The American Society of Neuroradiology and Society of Interventional Radiology made their case in a June letter to the Connecticut-based health insurer.